Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    ORIC-944

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ORIC To Report Rinzimetostat Ph1b Combo Data In mCRPC
    ORIC To Report Rinzimetostat Ph1b Combo Data In mCRPC

    27 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/27/3263751/0/en/ORIC-Pharmaceuticals-to-Report-Combination-Dose-Optimization-Data-From-Phase-1b-Trial-of-Rinzimetostat-in-Patients-with-mCRPC.html

    GLOBENEWSWIRE
    27 Mar 2026
    Share Share
    ORIC Pharma Unveils (ORIC-944) Preclinical Data At AACR 2026
    ORIC Pharma Unveils (ORIC-944) Preclinical Data At AACR 2026

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257727/0/en/ORIC-Pharmaceuticals-Announces-Preclinical-Rinzimetostat-ORIC-944-Presentations-at-the-2026-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    ORIC Pharma Outlines 2025 Operations And Future Milestones
    ORIC Pharma Outlines 2025 Operations And Future Milestones

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216908/0/en/ORIC-Pharmaceuticals-Provides-Operational-Highlights-for-2025-and-Anticipated-Upcoming-Milestones.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    ORIC Pharma's ORIC-944 Trial Shows Best-in-Class Results
    ORIC Pharma's ORIC-944 Trial Shows Best-in-Class Results

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187843/0/en/ORIC-Pharmaceuticals-Announces-Completion-of-Dose-Exploration-Portion-of-ORIC-944-Phase-1b-Clinical-Trial-and-Continues-to-Demonstrate-Potential-Best-in-Class-Efficacy-and-Safety.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share
    ORIC Presents Data on ORIC-944 Showing Promise in Solid Tumors
    ORIC Presents Data on ORIC-944 Showing Promise in Solid Tumors

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174568/0/en/ORIC-Pharmaceuticals-Presented-Preclinical-Data-at-the-EORTC-NCI-AACR-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics-Supporting-Best-in-Class-Potential-of-OR.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    ORIC Pharma Presents Preclinical Data on ORIC-944 at AACR 2025
    ORIC Pharma Presents Preclinical Data on ORIC-944 at AACR 2025

    28 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/28/3069677/0/en/ORIC-Pharmaceuticals-Presents-Preclinical-Data-to-Support-the-Potential-of-ORIC-944-as-a-Best-in-Class-PRC2-Inhibitor-for-the-Treatment-of-Prostate-Cancer-at-the-2025-American-Asso.html

    GLOBENEWSWIRE
    28 Apr 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.